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Abstract
Insulin resistance is the common denominator of several diseases including type 2 diabetes
and cancer, and investigating the mechanisms responsible for insulin signaling impairment
is of primary importance. A mathematical model of the insulin signaling network (ISN) is pro-
posed and used to investigate the dose-response curves of components of this network.
Experimental data of C2C12 myoblasts with phosphatase and tensin homologue (PTEN)
suppressed and data of L6 myotubes with induced insulin resistance have been analyzed
by the model. We focused particularly on single and double Akt phosphorylation and
pointed out insulin signaling changes related to insulin resistance. Moreover, a new charac-
terization of the upstream signaling of the mammalian target of rapamycin complex 2
(mTORC2) is presented. As it is widely recognized that ISN proteins have a crucial role also
in cell proliferation and death, the ISN model was linked to a cell population model and
applied to data of a cell line of acute myeloid leukemia treated with a mammalian target of
rapamycin inhibitor with antitumor activity. The analysis revealed simple relationships
among the concentrations of ISN proteins and the parameters of the cell population model
that characterize cell cycle progression and cell death.
Introduction
Insulin resistance represents the common denominator of a series of diseases, including obe-
sity, type 2 diabetes (T2D), metabolic syndrome and cancer. It arises from the impairment of
the insulin action, which induces consequently the hyper-secretion of insulin. The main path-
ways within the insulin signaling network (ISN) are well established [1,2,3], with the serine/
threonine protein kinase Akt/PKB and the two mammalian Target Of Rapamycin Complexes
(mTORC1 and mTORC2) playing a special role. Akt is phosphorylated on Thr308 by the phos-
phoinositide-dependent protein kinase-1 (PDK1) and on Ser473 by mTORC2 [4], and the
maximal Akt activity is achieved when the molecule is phosphorylated on both residues, allow-
ing the translocation of the insulin-regulated glucose transporters (GLUT4) in muscle and
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adipose tissue [5,6]. PDK1 and mTORC2 also respond to the activation of the insulin-like
growth factor 1 (IGF1) [3].
The kinase cascade through the insulin receptor (IR) up to mTORC1, as well as the
mTORC1 activation by amino acids and energy, are clearly assessed [7]. By contrast, the
upstream regulation of mTORC2 is not yet well-characterized [8]. The tuberous sclerosis com-
plex 1/2 (TSC1/TSC2) appears to be required for mTORC2 activation [2,9]. However, this view
was questioned in a study that reported experimental time courses of several proteins of the
ISN under amino acids and insulin stimulation [10]. Interpreting the data by a dynamic model
of the network, it was argued that mTORC2 activation pathway may originate from the IR or
the insulin receptor substrate-1 (IRS1), possibly via a variant of the phosphatidylinositol
3-kinase (PI3K) [10]. A still different view emerged from experiments in non-diabetic mice
both in vivo and in muscle biopsies, and in L6 cells exposed to a medium enriched with pro-
teins secreted by the small intestine of diabetic rats and to serum from insulin resistant humans
[11]. This study showed that jejunal factor/s induce insulin resistance and that these factors
activate mTORC2, as revealed by an increased value of Ser473 Akt phosphorylation, even in
the absence of insulin stimulation. The presence of such intestinal factors is also suggested by
the decrease of insulin resistance following bariatric surgery [12].
The mTORC1 substrate p70S6 kinase 1 (S6K1) is involved in the regulation of protein syn-
thesis and the growth of cell size, and active S6K1 inhibits IRS1 in a negative feedback loop [3].
Moreover, the Akt substrate Forkhead box protein O1 (FoxO1) is involved in the regulation of
proliferation and apoptosis, so the insulin signaling network has a major role not only in obe-
sity and diabetes but also in cancer [3,13,14].
Following the seminal papers of Wanant and Quon [15] and of Sedaghat et al. [16], several
studies have investigated the behavior of the ISN induced by insulin stimulus by developing
mathematical models and analyzing the experimental data. Some studies focused on the
response to a step increase in extracellular insulin concentration [15,16,17,18,19,20]. In partic-
ular, the mathematical model proposed by Kiselyov et al. [17] accounted for both the high and
low affinity sites in the two monomers of the insulin receptor. Brännmark et al. [18] studied
possible schemes that explain the peculiar behavior observed in the phosphorylation of the
insulin receptor and the insulin receptor substrate. More complete dynamical models, sup-
ported by the analysis of the time-course of protein concentrations after insulin stimulation,
were developed and investigated [10,19,20]. Complex dynamical models were proposed to rep-
resent the signaling through the ErbB receptors up to PI3K and Akt, with the aim of exploring
the response to an anticancer drug [21], and to model the insulin induced initiation of eukary-
otic translation [22].
The dose-response curves, i.e., the steady state concentrations at given insulin levels, were
considered in other studies. Giri et al. [23] and Wang [24] studied the behavior of the dose
response curves of components of the ISN versus the extracellular insulin concentration, to
determine the conditions that produce a hysteresis in the curves as the result of the interactions
between negative and positive feedback loops present in the system. Although the experimental
time-course of protein concentrations under constant insulin stimulation show that some pro-
teins may not achieve an evident steady state up to 2 hrs [10], the dose-response curves are
largely used in the literature to assess the behavior of ISN components at various levels of insu-
lin stimulation and to evaluate the response to perturbing agents and drugs.
Aim of the present study is to investigate the factors that affect the basal protein concentra-
tions and the dose-response curves of the ISN. Using the Michaelis-Menten scheme of chemi-
cal reactions, we developed a mathematical model of the network at the steady state, which
focuses on the single and double Akt phosphorylation and the upstream signaling of
mTORC2. Based on literature data of skeletal muscle lines, we show how the model can
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represent the effects of gene silencing. The factors that induce insulin resistance are modeled
according to the findings in [11]. Improved modeling of Akt and mTOR complexes is also
used here to simulate the ISN response in conditions such as TSC2 null and long-term rapamy-
cin treatment. In view of the close relationship between insulin resistance and cancer, mainly
due to Akt and mTOR signaling, we combined the insulin signaling model with a cell popula-
tion model in order to investigate the effects of mTOR inhibitors with antitumor activity on
the ISN proteins and on the cell population response.
Results
The scheme of our model in Fig 1 is based on the current view of the ISN structure [2,3,14,25].
Since Akt may be independently phosphorylated at Ser473 by mTORC2 and at Thr308 by
PDK1 [8], we included all the pathways that lead to the full Akt activation. mTORC2 is assumed
to be activated by the phosphatidylinositol 3,4,5-trisphosphate (PIP3), as suggested in [3,26],
and by a factor J not dependent on PI3K, which is possibly mediated through the growth factor
receptors [11]. The activation of mTORC1 is represented here in a rather simple way, omitting
the TSC inhibition by Akt and the consequent mTORC1 activation via the Ras homolog
enriched in brain (Rheb). The scheme also contains the direct Akt substrates glycogen synthase
kinase 3 (GSK3) and Forkhead box protein O1 (FoxO1). The activated S6K1 phosphorylates
IRS1 and Rictor in negative feedback loops [25]. A positive feedback loop from Akt to the pro-
tein tyrosine phosphatase 1B (PTP1B) is also included [16]. While the activation pathway to
mTORC2 through TSC2 (Huang, Dibble, Matsuzaki, & Manning, 2008) was not considered in
view of the results in [10], the present model does not include for simplicity some established
pathways of the network, for instance, the IR intracellular pool and the receptor recycling, the
TSC2 activation promoted by FoxO1 [27] and the S6K1 activation by GSK3 [28].
The chemical reactions within our ISN model are mostly represented by the classical
Michaelis-Menten scheme [29,30], and are discussed in S1 File (Text S1). Several assumptions
allowed us to simplify the model. Intracellular localization of proteins (cytosolic vs. mem-
brane-associated), as well as the intracellular trafficking, were neglected. The protein com-
plexes (e.g., mTORC1 and mTORC2) were treated as simple molecular components.
The kinetic equations for the concentrations of the proteins, that also contain the terms of
synthesis and degradation of substrates and enzymes, are reported in S1 File (Text S2). As our
aim is the analysis of the dose-response curves, we then derived the concentrations of the chemi-
cals at the equilibrium. Under the crucial assumption, as suggested in [31], that the degradation
rate constant of a complex enzyme-substrate is negligible compared with the sum of dissociation
and catalytic constants, the equilibrium equations take a rather simple form. The ISN model
equations in the normalized form used for the analysis of the muscle cell lines C2C12 and L6 are
reported in the section Models, Eqs (1)–(16). S1 Table gives the expressions of the parameters in
Eqs (1)–(16) in terms of the kinetic parameters of the equations in S1 File (Text S2).
C2C12 myoblasts
The experimental data in [32] display the normalized phosphorylation levels in C2C12 myo-
blast cells of IR(Tyr1146), Akt(Ser473) and (Thr308), GSK3β(Ser9), S6K1(Thr389), and AS160
(Thr642) at zero insulin and at insulin concentrations of 1, 10, and 100 nM, plus the normal-
ized concentrations of PIP3 and GLUT4pm at zero insulin and at an assigned insulin value. The
Authors report the data for control and PTEN-suppressed cells, where PTEN protein concen-
tration was reduced up to 10% of control. We used these data, except those of PIP3 and AS160
that were used for the prediction, to estimate the ISN model parameters. The positive feedback
loop from Akt to PTP1B was not included because IR phosphorylation data were similar in
Insulin Signaling in Insulin Resistance States and Cancer
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Fig 1. Scheme of the insulin signaling network. Activation by insulin (I) of insulin receptor (IR) catalyzes
tyrosine phosphorylation of IRS1. Phosphorylated IRS1 binds the p85 regulatory subunit of PI3K, activating
the p110 catalytic subunit. PI3K mediates phosphorylation of PI(4,5)-bisphosphate (PIP2) to PI (3,4,5)-
trisphoshpate (PIP3) near plasmamembrane (PM) and the phosphatase and tensin homologue (PTEN)
dephosphorylates PIP3 back to PIP2. PIP3 recruits Akt and PDK1 to PM, where PDK1 phosphorylates Akt at
Thr308 (phosphatase PP2A). mTORC2 is activated by PIP3 and by the factor J, and catalyzes Akt
Insulin Signaling in Insulin Resistance States and Cancer
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control and PTEN-silenced cells (Fig 2 panel A). As done in [20], the normalized experimental
data of pAkt(Ser473) were fit by the sum AktSn þ AktS;Tn , given by Eqs (10) and (11) in the sec-
tion Models, because the specific monoclonal antibody is likely to bind Akt phosphorylated on
Ser473 irrespective of the presence of the phosphorylated Thr308. Similarly, the data of pAkt
(Thr308) were fit by AktTn þ AktS;Tn .
Fig 2 shows the data of C2C12 cells, replotted from Ref [32] and used for the estimation of
the parameters of Eqs (1)–(16), with PTENn in Eq (6) set to one for control and to 0.1 for
PTEN-silenced data. Fig 2 also displays the optimal fitting curves computed by the model and
S2 Table reports the parameter estimates (with Ie,0.5 and S0.5 given instead of a0 and a1). Ie,0.5
was found equal to 44.68 nM. As the experimental data are re-normalized to have a unity value
at maximal insulin concentration in control, we computed the dose-response curves in Fig 2
according to this constraint.
A subset of model predictions is displayed in S1 Fig. Panel A shows the prediction, obtained
by the estimated model, of pAS160(Thr642) together with the data that were not used in the
estimation procedure. While the profile of pAS160(Thr642) data was followed rather accu-
rately, the model failed to predict PIP3 concentration data in the PTEN-silenced cells (panel
B). We note that if mTORC2 were activated by PI3K instead of PIP3, the model could not ade-
quately fit pAkt(Ser473) data at zero and low insulin in PTEN-silenced cells, nor the prediction
of PIP3 concentration data would improve (S1 Fig, panels C, D). The total pAkt
(AktTn þ AktSn þ AktT;Sn ) at 100 nM insulin in control is 8.61% of total Akt (S1 Fig panel F) and
GLUT4 at the plasma membrane is 48.3% of total GLUT4. These values agree with the model
results reported in [16], where pAkt is about 9% of total Akt and surface GLUT4 attains 40% of
total GLUT4 after 15 min 100 nM insulin.
S2 Fig shows the sensitivities of protein concentrations upon a ±10% perturbation of the esti-
mated parameters at the extracellular insulin concentration of 44.68 nM. As this concentration
equals Ie,0.5, the sensitivity to S0.5 is vanishing. The same occurs for the sensitivities to a12(below
10−5), whereas ad13 and a
g
17 have small values (S2 Table). The largest positive sensitivities are
found for a9 and a10, whose values were set equal (see S2 Table) as no data on the phosphoryla-
tion of PDK1 andmTORC2 were available. Parameters that directly affect downstream proteins,
as mTORC1 and S6K1, also affect the upstream proteins, as IRS1 and PI3K, because of signaling
through the negative feedback loop. The opposite behavior of IRS1Y and IRS1S is also noted.
As expected, PTEN deletion enhances the insulin response and basal level increased in almost
all proteins, according to the negative sensitivity to a8 of all proteins downstream PTEN, whereas
IRS1Y and PI3K are positively regulated (S2 Fig). In particular, PTEN protein suppression causes
an increase in basal Ser473 Akt phosphorylation, which may phosphorylate and deactivate FoxO1
with the possible enhancement of signaling to the pathways that regulate cell proliferation.
L6 myotubes
As shown in Fig 3, the data in [11] give the normalized phosphorylation levels in L6 cells of
pAkt(Ser473) and (Thr308) at zero insulin and at insulin concentrations of 0.1, 1, 10, and 100
nM. pGSK3β(Ser9) is reported at zero and 100 nM insulin. Moreover, pAkt(Ser473) and
pS6K1(Thr389) at zero insulin were measured in the presence of the inhibitors Rapamycin and
phosphorylation on Ser473 (phosphatase PHLPP). Maximal Akt activity is achieved when the molecule is
phosphorylated on both Thr308 and Ser473 residues, allowing translocation of GLUT4 glucose transporters
to PM. GSK3 and FoxO1 are direct Akt substrates. Akt also activates mTORC1, which in turn activates S6K1.
Activated S6K1 phosphorylates IRS1 and Rictor in negative feedback loops. The positive feedback loop from
Akt to PTP1B is also included. Feedback loops are represented by bold lines.
doi:10.1371/journal.pone.0154415.g001
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PP242 that targets both mTOR complexes [33]. The data were obtained in the control medium,
enriched by proteins secreted by jejunal mucosa of non-diabetic mice, and in medium enriched
by proteins secreted by the mucosa of diabetic mice (denoted in the following as conditioned
medium or db/db medium). Based on experiments in non-diabetic mice both in vivo and in
Fig 2. Experimental data of C2C12myoblast cells andmodel fitting. Data (mean ± SEM) replotted from Ref [32] for control
(black squares) and PTEN-suppressed (red squares) cells. Solid lines are the dose-response curves predicted by the model
for control (black) and PTEN-suppressed cells (red). (A) Relative pIR(Tyr1146). (B, C) Relative pAkt(Ser473) and pAkt
(Thr308). (D) Relative pGSK3β(Ser9). (E) Relative pS6K1(Thr389). (F) Relative GLUT4 at PM at zero (white box) and 100 nM
(gray box) insulin.
doi:10.1371/journal.pone.0154415.g002
Insulin Signaling in Insulin Resistance States and Cancer
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Fig 3. Experimental data of L6myotubes andmodel fitting. Data (mean ± SD) replotted from Ref [11] except panel D from
Ref [34]. Data (squares) and model fitting (solid lines) plotted in black for control and in blue for cells exposed to conditioned
(db/db) medium. (A, B)Relative pAkt(Ser473) and pAkt(Thr308). (C) Relative pGSK3β(Ser9) at zero (white box) and 100 nM
(gray box) insulin. (D) Relative 2-DG uptake in rat L6 myoblasts. (E) Relative pAkt(Ser473) at zero insulin in control (black) and
cells exposed to db/db medium (red), in the absence of inhibition and in cells treated with rapamycin (50 nM) and PP242 (500
nM). The red color indicates that experimental values do not preserve the increase in basal pAkt(Ser473) from control to db/db
medium in the absence of inhibition, and asterisks point out that these data were not used in model fitting. Green (no inhibitor),
yellow (rapamycin), and pink boxes (PP242) represent model fitting. (F)Relative pS6K1(Thr389) at zero insulin in the absence
of inhibition and in treated cells (the boxes represent model fitting).
doi:10.1371/journal.pone.0154415.g003
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muscle biopsies, and in L6 cells exposed to the db/db medium and to serum from insulin resis-
tant humans, it has been hypothesized that jejunal factor/s induce insulin resistance [11]. The
factor J that activates mTORC2, see Eq (8), has been included in the model to represent the
action of this putative factor.
We fit the experimental data assuming that J has negligible concentration in the control
medium and a larger concentration, to be estimated, in the db/db medium. To fit the data
obtained in db/db medium, we hypothesized that insulin resistance also increases because of
an increased IRS1 degradation due to enhancement of mTORC2 signaling [35]. This negative
feedback was represented by suitably tuning the parameters of PI3K. Fig 3 shows the experi-
mental data of L6 cells, replotted from [11] and [34], along with the optimal fitting curves, and
S2 Table reports the parameter estimates. We observe that a high value of pAkt(Ser473) at zero
insulin, as observed in Fig 3 panel A can only be obtained if mTORC2 is also activated through
a signaling pathway independent of PI3K, and if the Thr308 Akt phosphorylation is not
required for Ser473 phosphorylation.
Phosphorylation data measured in the experiments with db/db medium are fit with a value
of J substantially larger compared to control (0.07 vs. 0.001). pAkt(Ser473) at zero insulin is
largely increased, but its response to insulin is blunted (Fig 3A). The response of pAkt (Thr
308) and of pGSK3β(Ser9) is also depressed (panels B and C). The 2-DG uptake data reported
in Fig 3D were adequately fit by the model. The predicted 2-DG uptake in the presence of db/
db medium (panel D) was computed by assuming that the rate constants that regulate GLUT4
translocation to plasma membrane are smaller compared to control [5,6], see S2 Table.
The data measured in the presence of Rapamycin and PP242 are shown Fig 3 panels E-F.
The model adequately fits the inhibition of basal (no insulin) pS6K1(Thr389) both in control
and db/db medium (panel F). S6K1 inhibition leads in turn, because of attenuated negative
feedback, to a decrease in IRS1Sn and an increase in IRS1
Y
n (S2 Fig, panels A-D), thus enhancing
insulin signaling. In basal pAkt(Ser473) data (Fig 3, panel E), the poor prediction for cells
exposed to db/db medium is caused by experimental variability and the data were not used for
model fitting. In cells treated with Rapamycin, the attenuated negative feedback led to an
increase ofmTORC2n, thus enhancing pAkt. By contrast, PP242 affects Akt phosphorylation at
Ser473, so AktS and AkTT,S are strongly reduced. A subset of model predictions is displayed in
S3 Fig, where panel F gives a 3D representation of the components of pAkt. At 100 nM insulin,
total pAkt is 78.7% of total Akt in control. Overall, it appears that the present model provides
an adequate fitting of the L6 data.
S4 Fig shows the sensitivities of protein concentrations to the estimated model parameters
at the extracellular insulin concentration of 9.69 nM (estimated Ie,0.5). The general pattern of
the sensitivities for the L6 cells in control and db/db medium is similar to that found for
C2C12 cells, confirming that the model is able to represent both types of data. In addition, the
sensitivities to a
0
6 and a
0
23 are small according to the small values of estimates whereas, as
expected, the sensitivities to the factor J increase in cells exposed to the db/db medium com-
pared to control. The sensitivity to a12 is small in both C2C12 and L6 cells, suggesting that the
negative feedback loop from S6K1 to mTORC2 has a negligible role in these lines.
The L6 cell data were also analyzed in the presence of the positive feedback, with the con-
stant aP in Eq (4) set to a smaller value for the cells in db/db medium compared to control. The
results, however, did not appear to improve on those obtained with the present model.
Simulations with improved models of Akt and mTOR complexes
Three possible extensions of the models of Akt and mTOR complexes are here considered:
sub-cellular Akt localization, mTORC1 activation, and mTORC2 response to rapamycin.
Insulin Signaling in Insulin Resistance States and Cancer
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The trafficking of molecules within the cell is regulated by diffusion and active transport,
processes that require a complex mathematical treatment based on partial differential equa-
tions [36,37]. To give a simplified model of the sub-cellular localization of Akt, we have only
considered the Akt phosphorylation at Thr308. Therefore, we have Akt molecules in the cyto-
solic compartment (Aktcyt and pAktcyt), those located at the PM (Aktpm and pAktpm), and
those in the nucleus (pAktnuc). Fig 4 panel A shows a scheme of the model.
The equations of the Akt concentrations are given in S1 File (Text S3) and show that, at the
steady state, the three concentrations of phosphorylated Akt tend to be equal provided that
kncffi kcn and kmc ffi K15 PP2A. Aktcyt tends to be equal to Aktpm provided that K13PIP3 equals
K13 PDK1 and k−13 is much smaller than these two quantities also at low insulin levels. More-
over, kmcmust be much larger than K14 PP2A. Although we have no data ensuring that these
conditions are satisfied, they guarantee that most of Aktcyt safely reaches PM and is phosphor-
ylated, and that pAktpm is rapidly translocated from PM to cytosol where it has to phosphory-
late several substrates. In these conditions, the Akt model considered in S1 File (Text S1, Text
S2) and Eqs (9)–(11), where the sub-cellular localization was disregarded, can be considered
an adequate model of Akt kinetics in the steady state. We remark, however, that the transient
response of Akt concentrations to a sudden change in the insulin concentration is likely to be
different whether the sub-cellular localization is considered or not.
Fig 4 panel B shows the scheme of the improved model of mTORC1 activation. Eqs (12)–
(15) in S1 File (Text S3) give the normalized concentrations of the molecular components and
literature data provide information on the protein response to Akt. TSC2 phosphorylation
level at T1462 has a more than 10-fold increase in HEK-293 cells upon serum stimulation [38].
The increase in PRAS40 phosphorylation level at T246 may range from about 10-fold to
20-fold in isolated skeletal muscle with smaller values in heart, liver and adipose tissue [39].
These data provided constraints in the estimation of the parameters in Eqs (12)–(15), and
uniqueness of the estimates was guaranteed by setting φ = −0.67 (bPRAS = 3bmTORC1, i.e., the
rate of PRAS synthesis is three times that of the heterotrimer mTOR, raptor, mLST8) and
KmmTOR ¼ 104. To estimate the remaining parameters, we took the profiles of AktTn þ AktT;Sn
and ofmTORC1n as a function of Ie obtained from the model of L6 cells. The profile of AktTn þ
AktT;Sn was used as the input function in (12) and (15) of S1 File (Text S3), and the parameter
values that optimally reproducedmTORC1n profile were as follows: KTSC = 65.95, KRheb = 6.48,
KmTORC1 = 7.210−3, KPRAS = 16.72.
In the simulations presented in Fig 4, panels C-F, we used the complete ISN model of Eqs
(1)–(16) with Eq (14) ofmTORC1n replaced by Eqs (12)–(15) of S1 File (Text S3). The loss of
PRAS40 expression was represented in the model by a tenfold decrease of bPRAS compared to
control, with the consequent changes of KmTOR, K
m
mTOR and φ in (14)-(15) of S1 File (Text S3).
Fig 4C shows the decrease of PRAS40n and the increase ofmTORC1n in this condition, com-
pared to control. By contrast, PRAS40 overexpression with a twofold increase in bPRAS inhibits
mTORC1 activation. In Fig 4D, the normalized concentrations of T389 S6K1 under PRAS
knockdown and overexpression (pink and yellow boxes, respectively) follow the response of
mTORC1n shown in panel C. Under both PRAS and Rheb overexpression (orange boxes),
mTORC1 and S6K1 are no longer inhibited compared to control because GTP-loaded Rheb
overcomes the PRAS40-mediated mTORC1 inhibition, as pointed out in [38] and predicted by
Eq (14) in S1 File (Text S3). The results of the simulations in panel D appear to agree, qualita-
tively at least, with the increased T389 S6K1 phosphorylation shown by the blots in Fig 4E
(HEK293E cells) and Fig 5E (MEFs and HT-29 colon cancer cells) of [40].
To analyze the effect of chronic mTORC1 activation, we represented the ISN signaling in
TSC2-null cells by setting bTSC and thus KRheb to zero. Eq (13) of S1 File (Text S3) shows that
Insulin Signaling in Insulin Resistance States and Cancer
PLOS ONE | DOI:10.1371/journal.pone.0154415 May 5, 2016 9 / 26
Fig 4. Improvedmodeling of Akt andmTOR. (A) PIP3 recruits PDK1 and Akt to the plasmamembrane. At
the PM, Akt is phosphorylated by PDK1 and dephosphorylated by PP2A. Transport of not yet phosphorylated
Akt from PM back to cytosol is regulated by the rate constant k
−13. Phosphorylated Akt is transported to cytosol
(rate constant kmc) where it is dephosphorylated by PP2A or imported into the nucleus (kcn). Export from
nucleus is regulated by knc. (B) Phosphorylated Akt inactivates TSC2. Active TSC2 promotes Rheb binding to
GDP and TSC2 inactivation stimulates the conversion from Rheb/GDP to active Rheb/GTP, which in turn
Insulin Signaling in Insulin Resistance States and Cancer
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Rheb/GTPn attains its (maximal) unity value and mTORC1 concentration increases compared
to control (Fig 4E). Because of the enhanced negative feedback, PI3K, mTORC2 and Akt phos-
phorylated at S473 are downregulated. A highly decreased PI3K concentration compared to
control, as found in TSC2 null MEFs [41], was not obtained. A marked decrement might be
obtained from the present ISN model by imposing different values of the parameters, and
mainly by values of a4 larger than the value actually estimated in the L6 cells, so to increase the
extent of the negative feedback.
A model of the response of mTORC2 to long-term rapamycin treatment is given in S1 File
(Text S3). In the simulation of the response to long-term treatment (Fig 4F), the production
rate bmTORC2 of mTORC2 was set to 0.1 of control level to account for a value of α (the cell-
type specific parameter) close to the unity, according to Eq (19) of S1 File (Text S3). The
response of mTORC1, both in the short-term and the prolonged treatment, was instead repre-
sented by a tenfold decrease of the catalytic constant k3c (and thus of KmTOR) in (14) of S1 File
(Text S3), as done in the analysis of the data of L6 cells. Compared to control, short-term treat-
ment inhibits mTORC1, but enhances mTORC2 due to the downregulation of negative feed-
back. By contrast, the prolonged treatment strongly inhibits mTORC2 because rapamycin/
FKBP12 binds to newly synthesized mTOR and the formation of mTOR complex is prevented.
As bmTORC2 appears in the parameters aε15; a
ε
19 and a
g
19 of Akt Eqs (9)–(11), mTORC2 inhibition
causes a decrement of S473 as well as of double Akt phosphorylation and, as a consequence,
also mTORC1 is further downregulated. The simulation results agree qualitatively with the
reduced S473 Akt phosphorylation shown by the blots in Fig 2 of [42] for cells highly sensitive
to rapamycin, as the PC3 cells.
Response to mTOR inhibitors with antitumor activity
The response of the ISN and of an AML (acute myeloid leukemia) cell population to mTOR
inhibitors is studied here with reference to the dual ATP-competitive mTOR inhibitor
AZD8055 [43,44]. The study in [44] reports data of Akt and mTOR signaling pathways,
together with data that demonstrate the anticancer activity of the drug. Data include the inhibi-
tion of p70S6K(Thr389) and pAkt(Ser473) in the MV4-11 human AML cell line, in untreated
cells and at drug concentrations of 10, 100 and 1000 nM. The Authors also report the fractions
of cells in cell-cycle phases and the apoptotic fragments obtained by propidium iodide (PI)
staining and flow cytometry, the data of [3H]thymidine incorporation (labeling index, LI), the
fractions of annexin V and PI-positive cells, and the in vivo effect of the drug in mice bearing
MV4-11 xenografts.
The cell population response is represented by the mathematical model of Eqs (17)–(26),
described in the section Models, which is similar to the model proposed in [45] and is depicted
by the block scheme of Fig 5 panel A. The model parameters, to be estimated from the data in
control and in the treated populations, are the rate constant α of exponential growth (or
activates mTORC1. mTORC1 is also inhibited by PRAS40. The box including active mTORC1 and proline-rich
Akt substrate of 40 kDa (PRAS40) accounts for reaction (3) in S1 File (Text S3). (C) PRAS knockdown (KD:
KmTOR increased tenfold compared to control and φ = 0.7, pink boxes) and overexpression (OE: KmTOR halved
compared to control and φ = −5/6, yellow boxes) and effect on mTORC1 activation at 1 nM insulin. (D)
Normalized concentrations Rheb/GTP and of T389 S6K1 at 1 nM insulin with PRAS knockdown (tenfold bPRAS
decrease, pink boxes), PRAS overexpression (twofold bPRAS increase, yellow boxes), and with both PRAS
(twofold bPRAS increase) and Rheb (fivefold bRheb increase) overexpression (orange boxes). (E) Normalized
protein concentrations in TSC2-null cells at 1 nM insulin. (F) Response to short-term and long-term rapamycin
treatment of mTORC1 and mTORC2, and effect on Akt phosphorylation at 10 nM insulin. Short- and long-term
treatments: KmTOR in Eq (14) of S1 File (Text S3) set to 0.1 of control. Long-term-treatment: parameters aε15; a
ε
19
and ag19 of Akt Eqs (9)–(11) set to 0.1 of control.
doi:10.1371/journal.pone.0154415.g004
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Fig 5. Response of AML cell population to mTOR inhibitor with antitumor activity. (A) Scheme of model used for the analysis
of AML cell population data in the absence and presence of AZD8055. The blocks represent G0/G1, S and G2M cells, with the ×2
block denoting binary cell division. λ1 is the rate constant of G1S transition, T2 and T3 the transit times in S and G2M phases, and μ0
the rate constant of cell loss. D1–D3 represent cells lost from viable compartments but still measurable, and A the apoptotic bodies
and fragments, with μ0 0 the rate constant of cell fragmentation. (B) Data, replotted from Ref [44], of cell fractions in cell cycle phases
in control and cells treated with 10, 100, and 1000 nM AZD8055 (closed squares), and model fitting (solid lines). The panel also
displays data and fitting of LI normalized to control, and of total fraction of dead cells and fragments. (C) Correlation between data of
acridine orange staining in A549 cells, replotted from Ref [43], and fraction of dead cells
P3
i ¼ 1 fDi . (D) Relationship between the
decrease of pAkt(Ser473) (squares) and that of λ1 at increasing drug concentrations. Fitting line y = 1.03x/(0.1810−2+x), with y =
pAkt(Ser473) and x = λ1. A similar function fits the relation between GSK3β(Ser9) (triangles) and λ1. Data are normalized to control
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decline) of the population, the rate constant λ1 of the transition G1 S, the transit times T2 and
T3 in S and G2M, and the cell loss rate constants μ0 and μ00. The estimates, reported in S3 Table,
show the effects of the different drug concentrations on the cell population kinetics.
Fig 5B displays data and model fitting of the cell fractions in cycle phases, showing the cell
accumulation in G0/G1 and the depletion of S and G2M in the treated populations. The same
panel also displays data and model predictions of the LI and of the total fraction of dead cells
and fragments. The rate constant λ1 exhibits a marked concentration-dependent decrement,
whereas the transit times in S and G2M, and the rate constant μ0 of loss from the viable com-
partment, increase (S3 Table). Accordingly, α (population doubling time ln2/α = 3.86 days in
control) turns out to be negative in the treated populations (halving times 2.036, 1.364, and
0.783 days at 10, 100, and 1000 nM), confirming that a major factor that inhibits cell prolifera-
tion is the block of cells in the G0/G1 phase [46]. There is an intricate interplay between autop-
hagia and apoptosis [47]. We did not represent these pathways, hence the simple model used
cannot relate the loss parameters μ0 and μ00 to autophagia or apoptosis. However, as depicted
by Fig 5C, the fraction of dead cells
P3
i ¼ 1 fDi nicely correlates with the increase of acridine
orange staining reported in [43] for a different cell line, suggesting that μ0 might mainly be
related to cell death caused by autophagia.
To correlate the kinetics of the AML cell population with the response to AZD8055 of the
ISN, we accounted for the constitutive activation of PI3K/Akt signaling, frequently found in
AML [48], representing this activation by an “equivalent” insulin signal. To fit the pS6K1
(Thr389) inhibition profile in the MV4-11 human AML cell line in [44], we estimated the
parameters that regulate mTORC1 and mTORC2 inhibition (a10, a11, and a24 in Eqs (8) and
(14), keeping the other parameters to values estimated for L6 cells (S5 Fig panel B).
A simple nonlinear monotonic function provides a good fit of the relation between the
value of pAkt(Ser473), predicted by the insulin signaling model, and the population model
parameter λ1(Fig 5D), showing how these two quantities are reduced as drug concentration
increases and how the extent of the block of G1S transition is related to mTORC2 inhibition.
Similar functions also fit the relations between λ1 and pGSK3β(Ser9), cytosolic FoxO1 and
pS6K1(Thr389) (Fig 5D and S5 Fig panel A). Panel E depicts the relationship between the aver-
age cell cycle time, an index of the rate of protein synthesis, and pS6K1(Thr389). In panel F,
the model predicted pS6K1(Thr389) is plotted versus μ0, showing how mTORC1 inhibition is
also related with the increment of cell loss. S5 Fig panel C reports data and model fitting of
pAkt(Ser473) as a function of the dose, compared with data in MDA-MB-468 cells [43], and S5
Fig panel D represents the ratio cytosolic/nuclear FoxO1 predicted by Eq (12) along with data
in MDA-MB-468 cells [43].
Overall, the above findings agree with the notion that mTORC2 inhibition activates cyclins
D1-D2 via Akt(Ser473) and FoxO1 inhibition, and that mTORC1 inhibition activates autop-
hagy [3]. Rapamycin derivatives were indeed found to inhibit both mTOR complexes and
decrease the levels of CCND1 and CCND2 in AML [49].
Discussion
The ISN scheme here considered is based on a consolidated view that emerges from recent litera-
ture. The present model concentrates particularly on single and double Akt phosphorylation
and represented with the color code in panel C. (E) Decrease of normalized pS6K1(Thr389) with drug concentration and relation
with the average cell cycle time Tc = 1/λ1+T2+T3 predicted by the cell population model. Fitting line y = 17.71/(15.61+x). (F)
Decrease of pS6K1(Thr389) with the drug concentration and relation with the parameter μ0 predicted by cell population model.
Fitting line y = 3.6310−7/(3.1510−7+x3.57).
doi:10.1371/journal.pone.0154415.g005
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because recent studies [50] have shown that Akt activity is maintained almost unaltered when it is
phosphorylated only on Thr308, while Ser473 phosphorylation seems to play an independent role
in both insulin resistance and cancer. That Akt can accomplish its enzymatic function without
undergoing Ser473 phosphorylation is demonstrated by the finding that muscle-specific rictor KO
mice simply present with a moderately decreased insulin-stimulated glucose uptake and glucose
intolerance [50], but not diabetes. Thr308 Akt phosphorylation is in fact able to activate GLUT4
translocation and is sufficient to mediate the phosphorylation of glycogen synthase kinase 3.
Our model shares a common ground with models previously described in the literature, but
it differs in several ways. Specifically, in [10], [16] and [20] the time course of a dynamical
model response to an insulin pulse was provided, whereas model equations in our study are
solved at the steady state, giving the dose response curves. The present ISN model partly sim-
plifies and partly extends the model in [16] by accounting for both Ser473 and Thr308 pAkt,
GSK3β and FoxO1, the complexes mTORC1 and mTORC2, and the mTORC1 substrate S6K1.
The final set of equations at the steady state, Eqs (1)–(16), got a simple and clearly readable
form by neglecting the degradation of the complexes. We stress that a scheme where Akt can
be independently phosphorylated at Thr308 and Ser473 residues, and where both sites can lead
to complete Akt activation, has not, to our knowledge, been previously considered. Moreover,
the upstream mTORC2 signaling depends on two independent pathways mediated by PIP3
and by a signal possibly related to activation of IGF1 receptor [11]. The parameter estimates
reported in S2 Table are rather different between C2C12 and L6 cells, which however is not
surprising since C2C12 is a line of mouse myoblasts whereas L6 is a line of rat myotubes.
To fit the data from the L6 cells exposed to db/db medium [11], the following changes in
model parameters were done compared to control values. 1) the factor J much larger for cells
in db/db medium than in control represents the effect on the ISN of an external factor possibly
of intestinal origin. 2) a6 and a
0
6 smaller than in control represent in a simplified way a negative
feedback on IRS1 related to mTORC2 hyperactivation. 3) The putative GSK3β sequestration
(a
0
23 > 0). 4) The decrease of a28 and a29 in Eq (16) for GLUT4 represents a diminished capac-
ity of GLUT4 vesicles to reach plasma membrane. Notably, changes similar to those induced
on ISN by db/db medium were also induced by serum from insulin resistant humans compared
to serum from control subjects [11].
Comparison of the results obtained here by analyzing the data from L6 cells exposed to the
db/db medium with those presented in [20] suggests the following observations. The large
pAkt(Ser473) level observed at zero insulin in cells exposed to db/db medium (Fig 3A) could
not be fit by an Akt model in which Thr308 Akt phosphorylation is necessary for phosphoryla-
tion at Ser473. The model-predicted profile of 2-DG uptake in the presence of db/db medium
(Fig 3D) was computed here by reducing the rate constants that regulate GLUT4 translocation.
Actually, in T2D subjects, GLUT4 mRNA and protein levels are reduced in adipose tissue
(GLUT4 concentration reduced to 50% of control in [20]) but not in skeletal muscle [5], so a
defective regulation of GLUT4 translocation may contribute to insulin resistance in L6 cells
exposed to db/db medium. Further, AS160 is inhibited by pAkt(Ser473) and fully activated Akt
in the model proposed in [20], whereas AS160 is here inhibited by pAkt(Thr308) and fully acti-
vated Akt. Indeed, muscle-specific deletion of rictor in mice reduced pAkt(Ser473) to less than
10% of control, but pAS160(Thr642) was still at 80% of control, with data from glucose and
insulin tolerance tests not substantially different from control [50].
Akt, mTOR and cell proliferation
Since our ISN model focuses on Akt and its phosphorylated forms, we used the model to pre-
dict the disjoint effect of the two phosphorylated forms of Akt in antitumor drugs. The protein
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kinase inhibitor 7-Hydroxystaurosporine (UCN-01) used in cancer therapy induces insulin
resistance in humans [51]. UCN-01 inhibits Thr308 but not Ser473 Akt phosphorylation and
impairs Akt kinase activity with subsequent inhibition of GLUT4 translocation to cellular
membrane [51]. Our model is appropriate to study this effect and Fig 6 shows indeed the
marked decrease of AktTn and Akt
T;S
n , with the resulting insulin resistance elicited by the drug
(GLUT4pm increase of 61.8% in control and 36.7% in treated cells, a reduction in the range of
glucose transport inhibition reported in [51]).
Fig 5 (panels D-F) and S5 Fig (panel A) highlight the simple relationships found between
model-predicted changes in the concentrations of proteins of the ISN, induced by mTOR inhibi-
tion, and changes in the AML cell population model parameters that correspond to alterations
of the proliferative capacity of the population. The relations found are a rough representation of
the complex machinery that regulates cell cycle progression, cell quiescence, and occurrence of
cell death. Indeed, we found relationships between the rate constant λ1 of the G1S transition
and different ISN proteins (pAkt(Ser473), pGSK3β(Ser9), FoxO1 and pS6K1(Thr389)), but the
molecular pathways that coordinate the action of these proteins in cell cycle regulation remain
undetermined. Similarly, pS6K1(Thr389) is related to parameters of cell cycle progression and
cell death, but its specific role in these pathways is not specified. The population model of Fig
5A is far from the complexity and richness of behaviors exhibited by the real system. Sophisti-
cated models have been proposed to represent the reactions involving cyclins and cyclin-depen-
dent kinases, see for instance a complex model of cell cycle control in mammalian cells [52].
In summary, the present ISN model permits to investigate the insulin signaling network in
the insulin resistance states and in cancer, focusing on the role played by Akt phosphorylated
at Ser473 and by the mTOR complexes, as well as on the drug effects. Although the numerical
values of model parameters will certainly change with the cell type, the general structure of the
model should be considered valid for any cell type as shown by the qualitative agreement
observed between model predictions and the experimental data from cell types different from
skeletal muscle, such as AML cells, MEFs and HT-29 cells. Model behavior has been tested on
a variety of conditions: muscle cells with Pten KO or with induced insulin resistance, knock-
down and overexpression of PRAS, TSC2-null cells, cells treated with rapamycin and antican-
cer drugs such as AZD8055 and UCN-01. The proposed model should thus be useful to
integrate the experimental research leading to translationally relevant findings.
Models
ISN model equations in normalized form
To reduce the number of unknown parameters, the model equations reported in S1 File (Text
S2) are rewritten in a simple non-dimensional form. We assume that synthesis rate and degra-
dation rate constants do not change with time and do not depend on the insulin signal. This
assumption may fail during chronic insulin treatment: e.g., after 12 h treatment, IRS1 amount
is reduced to 13.6% of control level in 3T3-L1 adipocytes [53]. However, experimental data
and model simulations of insulin signaling pathway [10,16,19,20], show that the response to a
step insulin increase may reach a steady state in a shorter time, so the horizon is here limited to
times that do not include these long-range changes.
The concentrations of all molecules, except insulin and factor J, are normalized to the ratio
of production rate b (expressed as concentrationtime−1) over degradation rate constant μ
(time−1) and denoted by the subscript n. All normalized concentrations are nonnegative and
smaller than the unity for any value of total insulin concentration Ie. The model parameters are
modified accordingly, and are combinations of the original parameters of the kinetic equations
of S1 File (Text S2), as reported in S1 Table.
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Fig 6. Response of the insulin signaling network to the Akt inhibitor UCN-01 in L6 cells. (A- C)Model predictions of
AktTn ; Akt
S
n, and Akt
T;S
n at 1 and 100 nM insulin in control (white boxes) and in cells exposed to UCN-01 (black boxes), obtained
by a tenfold decrease of the PDK1 parameter a9. The plots show the marked decrease of AktTn and Akt
T;S
n , with the resulting
increase in AktSn in treated cells compared to control. (D) The model prediction of GLUT4 concentration at plasmamembrane
highlights the insulin resistance elicited by the drug. (E) S6K1n reduction due to drug action on PDK1. (F) IRS1
Y
n enhancement
caused by the weakening of negative feedback.
doi:10.1371/journal.pone.0154415.g006
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From Eqs (25)-(26) in S1 File (Text S2) we obtain the equation for total tyrosine phosphory-
lated IR in normalized form (i.e., normalized to bIR/μIR). Assuming for simplicity that the posi-
tive feedback is not active, we set PTP1Bn = 1 and we have the following simplified expression:
IRYn ¼
IRY þ IRYb
ðbIR=mIRÞ
¼ ab þ I
ab þ a0 þ I
; ð1Þ
where IRYb ¼ ab=ðab þ a0Þ represents the basal (no insulin) tyrosine autophosphorylation, and
the free insulin concentration I is expressed as a function of total insulin Ie by
I ¼ 1
2
ððab þ a0 þ a1  IeÞ þ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðab þ a0 þ a1  IeÞ2 þ 4ðab þ a0ÞIe
q
Þ: ð2Þ
Since IRYb can be experimentally measured, ab can be written as a0 ρ/(1−ρ), where ρ denotes
this experimental value. Instead of a0 and a1, we used the two following quantities that have a
more evident meaning: the value Ie,0.5 of Ie at IRYn ¼ 0:5, and the slope of IRYn at Ie,0.5, S0.5.
From Eqs (1) and (2) these quantities are obtained as
Ie;0:5 ¼ a0 þ
a1
2
  1 2r
1 r ; S0:5 ¼
1 r
a1 þ 4a0ð1 rÞ
;
where Ie,0.5 has the dimension of a concentration and S0.5 is a concentration
–1.
If the protein phosphatase PP is constant, Eqs (33)-(34) in S1 File (Text S2) are rewritten
with IRS1Y and IRS1S normalized to bIRS1/μIRS1 as follows:
IRS1Yn ¼
IRYn
ða2 þ a3PTP1BnÞð1þ a4S6K1nÞ þ IRYn
ð3Þ
IRS1Sn ¼
ða2 þ a3PTP1BnÞa4S6K1n
ða2 þ a3PTP1BnÞð1þ a4S6K1nÞ þ IRYn
;
where all the parameters are non-dimensional. Eq (35) of S1 File (Text S2) becomes
PTP1Bn ¼
1
1þ aPAktS;Tn
: ð4Þ
In the absence of the positive feedback, aP = 0 and PTP1Bn = 1. From Eq (3) it is found, as
expected, that IRS1Yn increases with IR
Y
n and so with Ie, provided that PTP1Bn and S6K1n are
constant. However, the downstream kinase S6K1 exerts an inhibitory effect on the IRS1 tyro-
sine phosphorylation (negative feedback). In addition, the fully phosphorylated Akt inhibits
the phosphatase PTP1B as seen by Eq (4), so Akt phosphorylation might exert a positive feed-
back on insulin signaling, especially upon inhibition of S6K1.
Proceeding similarly, Eq (36) of S1 File (Text S2) normalized to bPI3K/μPI3K rewrites as
PI3Kn ¼
a6ðIRS1Yn Þ2
1þ a06IRS1Yn þ a6ðIRS1Yn Þ2
; ð5Þ
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and (37)-(38) become
PIP3n ¼
PI3Kn
a7 þ a8PTENn þ PI3Kn
ð6Þ
PDK1n ¼
a9PIP3n
1þ a9PIP3n
: ð7Þ
For the mTOR complex 2, Eq (39) of S1 File (Text S2) provides the following equation:
mTORC2n ¼
a10PIP3n þ a11 J
1þ ð1þ a12S6K1nÞðam10 þ a10PIP3n þ a11 JÞ
ð8Þ
where J is the factor that induces insulin resistance possibly via the IGF1 receptor [11], and a11
is the inverse of a concentration.
Since Thr308 and Ser473 Akt phosphorylation may be independently activated [8] two
pathways may be followed to achieve full Akt activation, as shown in Fig 1. Assuming the phos-
phatases PP2A and PHLPP (and so γ, δ, ε, η, θ, see S1 File (Text S2) constant, Eqs (40)–(42) for
the phosphorylated Akt are rewritten as follows:
AktTn ¼
PDK1n
D01
ðad13ag17ayε PDK1n þ aε15ðad17  ag17aZdÞmTORC2n þ ad13Þ ð9Þ
AktSn ¼
mTORC2n
D01
ðaε15ag19aZd mTORC2n þ ad13ðaε19  ag19ayεÞPDK1n þ aε15Þ ð10Þ
AktS;Tn ¼
PDK1nmTORC2n
D01
ðaε15ad17ag19mTORC2n þ ad13aε19ag17PDK1n þ aε15ag17 þ ad13ag19Þ ð11Þ
with
D01 ¼ ad13ag17PDK12nðaε19mTORC2n þ ayεÞ þ aε15ag19mTORC22nðad17PDK1n þ aZdÞ
þ PDK1nmTORC2nðad13ðaε19  ag19ayεÞ þ aε15ðad17  ag17aZdÞ þ ag17ðaε15 þ aε19aZdÞ þ ag19ðad13
þ ad17ayεÞ  ad17aε19Þ þ PDK1nðad13 þ ag17ayεÞ þmTORC2nðaε15 þ ag19aZdÞ þ 1:
Eqs (9)–(11) show that in the absence of insulin, when the concentrations of PDK1, AktT
and AktS,T are likely to be small, AktS concentration may still be large because of factor J signal-
ing via mTORC2. This behavior cannot be described by a hierarchical scheme in which the
Thr308 Akt phosphorylation is necessary for the phosphorylation at Ser473. Akt phosphoryla-
tion at threonine and serine measured at zero insulin may be related to basal autophosphoryla-
tion of insulin receptor.
Concerning the Akt substrates, the normalized cytoplasmic FoxO1 is given by
FoxO1n ¼
a21ðAktSn þ AktT;Sn Þ
1þ a21ðAktSn þ AktT;Sn Þ
; ð12Þ
and the normalized concentration of phosphorylated GSK3β is
GSK3bn ¼
a23ðAktTn þ AktT;Sn Þ
1þ a023W þ a23ðAktTn þ AktT;Sn Þ
; ð13Þ
whereW represents the putative factor that promotes GSK3β sequestration [54].
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Eq (45) becomes
mTORC1n ¼
a24ðAktTn þ AktT;Sn Þ
1þ a24ðAktTn þ AktT;Sn Þ
: ð14Þ
For the activation of S6K1, Thr229 S6K1 phosphorylation by PDK1 follows Thr389 phos-
phorylation by mTORC1 [55]. So from (46) we have:
S6K1n ¼
a26mTORC1n  a27PDK1n
1þ a26mTORC1n þ ðam26 þ a26mTORC1nÞa27PDK1n
: ð15Þ
Eq (47) for the normalized GLUT4pm(here denoted as GLUT4n) is rewritten as
GLUT4n ¼
a28 þ a29ðAktTn þ AktT;Sn Þ
1þ a30ðAktTn þ AktT;Sn Þ
; ð16Þ
where a28< 1, a29, and a30 (with a29< a30) may be easily derived from the expression of
GLUT4pm in (47), see S1 File (Text S2). Parameters a28, a29, a30 account in a simple way for the
various steps that promote GLUT4 translocation to plasma membrane [6].
Given the concentrations of insulin and of the factor J, Eqs (1)–(16) provide the dose-
response curve of each component in the ISN scheme of Fig 1. Note that all model parameters,
except Ie,0.5 and S0.5, are nondimensional, and are generally a ratio between the specificity con-
stant times the ratio b/μ of the kinase, and the same quantity of the phosphatase. In some cases,
a rate constant substitutes the specificity constant.
Parameter estimation. Eqs (1)–(16) were solved numerically by reducing to a system of
only two variables, for instance PDK1n andmTORC2n. The parameters were estimated by fit-
ting model solutions to data through minimization of a least-squares index. We used a local
optimization routine implementing a derivative-free algorithm for bound constrained optimi-
zation (Package SDBOX available at the Software Library of the Department of Computer and
System Science, Sapienza University of Rome) and the parameters were constrained to be non-
negative. Since a0 and a1 are related to Ie,0.5 and S0.5 by the equations
a0 ¼
1
2S0:5
 Ie;0:5
1 2r
 
1 r
1 2r ; a1 ¼ 4Ie;0:5
1 r
1 2r
1
S0:5
 
1 r
1 2r ;
the terms in parenthesis were constrained to be positive to ensure the positivity of a0 and a1.
Moreover, in view of the meaning of parameters (see S1 File (Text S2)), the quantities ad17 
ag17aZd and a
ε
19  ag19ayε in Eqs (9)–(11) were constrained to be positive. Also, we considered
that ag17a
ε
19aZd þ ag19ad17ayε  ad17aε19 in D01 equals ad17aε19 ðmAkt=gÞ with μAKt/γ 1.
To further reduce the number of parameters to be estimated, a2, a7 and a
m
10 in Eqs (3), (6)
and (8), that are likely to be small, were set to zero and we assumed a9 = a10 (see S2 Table) as
no data on the phosphorylation of PDK1 and mTORC2 were available.
In particular, for the parameter estimation of C2C12 data, we assumed that: i) the factor J is
negligible and then a11 in Eq (8) was set to zero; ii) a
0
23 in Eq (13) was also set to zero; iii) the
parameter aP of positive feedback in Eq (4) was set to zero because IR phosphorylation was
similar in control and PTEN-silenced cells (see Fig 2 panel A of main text); iv) basal IR autop-
hosphorylation at zero insulin was set to 0.03 in view of the data in [32].
We fit experimental data of L6 cells with the following assumptions: i) J has negligible con-
centration in control medium and a larger concentration, to be estimated, in db/db medium; ii)
insulin resistance also occurs because of increased IRS1 degradation via a negative feedback
due to enhancement of mTORC2 signaling [35]. Therefore, to fit the data of cells exposed to
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db/db medium, we reduced the values of a
0
6 and a6 in Eq (5) according to a twofold increase of
IRS1 degradation rate constant (μIRS1); iii) we changed AktTn into Akt
S
n in Eq (13) of GSK3β and
estimated a
0
23 withW = 1 for db/db data; iv) the action of Rapamycin was accounted for by
reducing a24 in Eq (14) by a factor 0.1, and the action of PP242 by reducing a10 and a11 in Eq
(8) and a24 by a factor 0.15. S2 Table reports the estimates of model parameters obtained from
the data of C2C12 and L6 cells.
The sensitivities of the normalized concentrations of proteins with respect to model param-
eters were computed as derivative of log concentration with respect to log parameter at the
optimum. The use of these (relative) sensitivities provides nondimensional quantities that do
not depend on the absolute values of concentrations and parameters. Sensitivities were evalu-
ated numerically upon a ±10% perturbation of the parameters. The results are presented in the
form of matrices where numerical values, which are positive for a positive regulation and nega-
tive for an inhibition, are converted to a color.
Model of cell population response to mTOR inhibitor with antitumor
activity
To analyze the behavior of the AML cell population we used a mathematical model based on
the age formalism, represented by the block diagram of Fig 5A. Denoting by N1(t) the number
of G0/G1 cells at time t, and by ni(ai, t) the cell density at time t with respect to age ai, with
i = 2,3 for cells in S and G2M phases, we have the balance equations
d
dt
N1 ¼ ðl1 þ m0ÞN1ðtÞ þ 2n3ðT3; tÞ ; ð17Þ
@
@t
niðai; tÞ þ
@
@ai
niðai; tÞ ¼ m0niðai; tÞ ; i ¼ 2; 3; ð18Þ
with boundary conditions
n2ð0; tÞ ¼ l1N1ðtÞ ; n3ð0; tÞ ¼ n2ðT2; tÞ;
where λ1 is the rate constant that regulates the G1 to S phase transition, T2 and T3 are the tran-
sit times in S and, respectively, G2M phases, and μ0 is the rate constant (taken equal for all
cycle phases) of cell loss from the compartments of viable cells. The number of S-phase cells at
time t, N2(t), is given by
R T2
0
n2ða2; tÞda2, and similarly for the number of G2M cells, N3(t).
We observe that, in this simple scheme of cell progression across cell cycle, the rate constant
λ1 represents the activity of the cyclins (as cyclin D) and the cyclin-dependent kinases that reg-
ulate the G1 to S transition. The rate constant μ0 may be related to the activity of the proteins
that regulate the autophagia and/or the early phases of apoptosis.
As in [45], we assumed that cells lost from the viable population can still be transiently mea-
surable, and so are counted in the phase fractions obtained by flow cytometry (see Fig 3 in Ref
[44]). Denoting the number of cells lost from the three viable compartments by Di(t), i = 1–3
(Fig 5A in the main text), we write
d
dt
Di ¼ m00DiðtÞ þ m0Ni; ð19Þ
with μ00 a rate constant of cell fragmentation related to apoptosis. Apoptotic bodies and
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fragments are eventually gathered in a further compartment that obeys the equation
d
dt
A ¼ mdegAðtÞ þ m00ðD1ðtÞ þ D2ðtÞ þ D3ðtÞÞ; ð20Þ
where the material that leaves this compartment with rate constant μdeg is no longer
measurable.
Assuming that the cell population is in balanced exponential growth (or is declining under
the treatment) with rate constant α, the following relation holds:
aþ m0 þ l1 ¼ 2l1 eðaþm
0ÞðT2þT3Þ; ð21Þ
where +μ0 > 0. The fractions of cells in the cell cycle phases, measured by PI staining and flow
cytometry, are derived accounting for the dead cells in compartments Di(t), i = 1–3, together
with the viable cells in the respective phase. So, for instance, fG1 is computed as (N1+D1)/Ntot,
with Ntot the total amount of cells and fragments. We have:
fG1 ¼
ðaþ m0Þðaþ mdegÞðaþ m00 þ m0Þ
ðaþ m0 þ l1ð1 eðaþm0ÞðT2þT3ÞÞÞðm00m0 þ ðaþ mdegÞðaþ m00 þ m0ÞÞ
; ð22Þ
fS ¼
l1ð1 eðaþm0ÞT2Þðaþ mdegÞðaþ m00 þ m0Þ
ðaþ m0 þ l1ð1 eðaþm0ÞðT2þT3ÞÞÞðm00m0 þ ðaþ mdegÞðaþ m00 þ m0ÞÞ
; ð23Þ
fG2M ¼
l1e
ðaþm0ÞT2ð1 eðaþm0ÞT3Þðaþ mdegÞðaþ m00 þ m0Þ
ðaþ m0 þ l1ð1 eðaþm0ÞðT2þT3ÞÞÞðm00m0 þ ðaþ mdegÞðaþ m00 þ m0ÞÞ
; ð24Þ
and the fraction of apoptotic materials in the subG1 region of the PI fluorescence histogram is
given by fA = 1−fG1−fS−fG2M. The total fraction of dead cells and fragments is
fDead ¼
m0ðaþ mdeg þ m0Þ
m00m0 þ ðaþ mdegÞðaþ m00 þ m0Þ
: ð25Þ
The effect of the drug on cell cycle progression, assessed by (3H)thymidine incorporation
(see S3 Fig in [44]), is measured by the labeling index (LI), which is derived in the above model
by writing an equation for the number of labeled cells [45]. We have
LIðDÞ ¼ l1ðaþ m
00Þ
ðaþ m0Þðaþ m00 þ m0Þ fG1

eaDð1 eðaþm0ÞðT2þDÞÞ
þm0em00D ðe
ðaþm00ÞD  1Þ
aþ m00 
eðaþm
0ÞT2ðeðm0m00ÞD  1Þ
m0  m00
 
; ð26Þ
where Δ is the length of the labeling period (Δ = 6 hrs [44]).
Parameter estimation. The unknown parameters in Eqs (21)–(26), to be estimated from
the available data in the control and in the treated cell populations, are α, λ1, T2, T3, μ0, μ00 and
μdeg. However, Eq (21) is an independent relationship among parameters that actually reduces
the number of unknowns. While α, λ1, T2, T3, μ0, μ00 are expected to be different in the control
and in the populations treated with different drug doses, it is likely that μdeg does not change
and, for simplicity, is taken equal to the value of μ00 in the control.
The growth rate constant α of the untreated population was estimated from the growth
curve of tumor size in the xenograft, and we assumed that the same α value holds for the MV4-
11 cell line. From the cell fractions in cell-cycle phases and the fraction of PI-positive cells
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represented by fDead in Eq (25), we estimated λ1, T2, T3, μ0, μ00 by least squares using Eqs (21)–
(25). Eq (26) provided the value of the labeling index in control, not given in [44]. The value of
α in treated cells was not available. The LI values in treated populations, reported in S3 Fig of
[44] as ratios treated/control, were multiplied by the LI of control (31.2%) to obtain the actual
values to be compared with model-predicted LI.
Supporting Information
S1 Fig. Experimental data of C2C12 myoblasts (not used in the parameter estimation) and
model predictions. Data (mean ± SEM) in panels A and B are replotted from Ref [32] of main
text. (A) Relative pAS160 (Thr642) concentration in control (black) and PTEN-suppressed
(red) cells, together with the dose-response curves predicted by the model. The equation for
pAS160 (Thr642) (inactive form) is given by
pAS160n ¼ 0:5 ðAktTn þ AktT;Sn Þ=½1þ 0:5 ðAktTn þ AktT;Sn Þ. (B) Relative PIP3 concentration in
control (black squares) and PTEN-suppressed (red squares) cells with model prediction at zero
insulin (white boxes) and 10 nM insulin (blue boxes). (C, D) Fitting of the relative pAkt
(Ser473) and prediction of relative PIP3 in the hypothesis that mTORC2 is activated by PI3K
instead of PIP3. (E)Model prediction of PDK1n in control and PTEN-suppressed cells at zero
(white boxes) and 100 nM insulin (gray boxes). (F)Model prediction of total pAktn in control
and PTEN-suppressed cells at zero (white boxes) and 100 nM insulin (gray boxes).
(PDF)
S2 Fig. Sensitivity analysis for the ISN model of C2C12 myocytes. The plot shows the sensi-
tivities of protein concentrations to the estimated parameters of the model at the extracellular
insulin concentration of 44.68 nM.
(PDF)
S3 Fig. Model predictions for L6 myotubes. (A, B)Model prediction of IRS1Yn (panel A) and
IRS1Sn (panel B) for cells in control medium at zero and 10 nM insulin in the absence of inhibi-
tor (green), and in the presence of 50 nM rapamycin (yellow) and 500 nM PP242 (pink). (C,
D)Model predictions as in (A) and (B), but for cells exposed to db/db medium. Panels A-D
show the different effect of decreased negative feedback on tyrosine and serine residues of
IRS1. (E) Plot of values assumed by PDK1n (abscissa) andmTORC2n (ordinate) when I e
increases from zero to 100 nM for control and db/db medium. (F) 3D plot of ktTn ; Akt
S
n, and
AktT;Sn as a function of PDK1n andmTORC2n according to Eqs (9)–(11) in Main Text. With the
present estimates of Akt model parameters, AktSn increases withmTORC2n and decreases with
PDK1n, while AktT;Sn , and less clearly Akt
T
n , increase with both PDK1n andmTORC2n.
(PDF)
S4 Fig. Sensitivity analysis for the ISN model of L6 myotubes. The plot shows the sensitivi-
ties of protein concentrations to the estimated parameters of the model at the extracellular
insulin concentration of 9.69 nM for control cells (upper panel) and cells in db/db medium
(lower panel).
(PDF)
S5 Fig. ISN response to the mTOR inhibitor AZD8055. (A) Relationship between the
decrease of pS6K1 (Thr389) (squares) and that of λ1 at increasing concentrations of the drug.
The fitting line has equation y = 1.10 x/(0.3510-2+x), with y = pS6K1 (Thr389) and x = λ1. A
similar function fits the relation between FoxO1cyt (triangles) and λ1. Data are normalized to
control and represented for the different drug concentrations as control (blue), AZD10 (red),
AZD100 (green), AZD1000 (cyan). (B) Normalized data (mean ± SD) of pS6K1 (Thr389) vs
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AZD8055 concentration (green diamonds) replotted from [44] and model outputs (black
squares), together with the fitting line y = 6.35/(6.34+x0.716). (C, D) Decrease of pAkt (Ser473)
(panel C) and of the ratio between cytosolic and nuclear FoxO1 concentration (panel D) with
increasing AZD8055 concentration as computed by the present model (black squares). Fitting
lines have equations similar to that in panel B. The green diamonds and lines, replotted from
Ref [43], show the decrease of the same proteins in different cells.
(PDF)
S1 File. Supporting Information Text. Text S1: Summary of reactions within the insulin sig-
naling network. Text S2: Kinetic and equilibrium equations. Text S3: Improved activation
model of Akt and mTOR complexes.
(DOCX)
S1 Table. Expression of ISN model parameters in Eqs (1)–(16) of section Models in terms
of the kinetic parameters of the equations in S1 File (Text S2).
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